SEARCH BY

Issuer directory Issuer directory
KEYWORDS
COMPANIES / ISIN
TYPE OF INFORMATION
INDUSTRY

Start search  ADVANCED SEARCH

COMPARTMENTS / INDICES

France
America
Asia
Oceania
Africa
Europe

MSI NEWS

FEEDS

My RSS My Google Microsoft Live My Yahoo

INDEX SEARCH RESULT

2019.01.22 | 22:51 | Permanent Information Releases / Operations

English version HTML (w) Mail

SIKA

puce SIKA AG SUCCESSFULLY COMPLETES THE OFFERING OF CHF 1,300 MILLION SUBORDINATED MANDATORY CONVERTIBLE NOTES DUE 2022 - HTML (w)

2019.01.22 | 22:51 | Permanent Information Releases / Operations

German version HTML (w) Mail

SIKA

puce SIKA AG-ERFOLGREICHE PLATZIERUNG DER PFLICHTWANDELANLEIHE IN HÖHE VON CHF 1,300 MILLIONEN MIT FÄLLIGKEIT IN 2022 - HTML (w)

2019.01.22 | 17:35 | Permanent Information Releases / Operations

English version HTML (w) Mail

SIKA

puce SIKA AG LAUNCHES OFFERING OF UP TO CHF 1,300 MILLION SUBORDINATED MANDATORY CONVERTIBLE NOTES DUE 2022 - HTML (w)

2019.01.22 | 17:35 | Permanent Information Releases / Operations

German version HTML (w) Mail

SIKA

puce SIKA AG LANCIERT EINE PFLICHTWANDELANLEIHE IM BETRAG VON BIS ZU CHF 1'300 MILLIONEN MIT FÄLLIGKEIT IN 2022 - HTML (w)

2019.01.22 | 07:00 | Permanent Information Releases / Sales and Revenues

English version HTML (w) Mail

SGS

puce SGS 2018 Full Year Results - HTML (w)

2019.01.22 | 06:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

VIFOR PHARMA

puce Updated Analysis of Pivotal Study Reveals: Proactive, High Dosage of Venofer® Significantly Reduces Risk of Death or Major Cardiovascular Events in Haemodialysis Patients - HTML (w)

2019.01.22 | 05:45 | Permanent Information Releases / Sales and Revenues

English version HTML (w) Mail

UBS

puce UBS: 2018 PBT +19% to USD 6.4bn - HTML (w)

2019.01.17 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce FDA accepts Roche's supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for initial treatment of metastatic non-squamous non-small cell lung cancer - HTML (w)

2019.01.08 | 07:15 | Permanent Information Releases / General Company News

English version HTML (w) Mail

NOVARTIS

puce Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease - HTML (w)

2019.01.08 | 05:15 | Permanent Information Releases / Sales and Revenues

English version HTML (w) Mail

SIKA

puce 2018 SALES EXCEED CHF 7 BILLION FOR THE FIRST TIME - STRONG GROWTH OF 13.7% - HTML (w)

2019.01.08 | 05:15 | Permanent Information Releases / Sales and Revenues

German version HTML (w) Mail

SIKA

puce UMSATZ 2018 ERSTMALS ÜBER CHF 7 MILLIARDEN - STARKES WACHSTUM VON 13.7% - HTML (w)

2019.01.08 | 05:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

SIKA

puce SIKA MADE BINDING OFFER TO ACQUIRE PAREX - HTML (w)

2019.01.08 | 05:00 | Permanent Information Releases / General Company News

German version HTML (w) Mail

SIKA

puce SIKA UNTERBREITET VERBINDLICHES ANGEBOT ZUR ÜBERNAHME VON PAREX - HTML (w)

2019.01.07 | 23:02 | Permanent Information Releases / General Company News

English version HTML (w) Mail

NOVARTIS

puce Sandoz and Pear Therapeutics Announce US Launch of reSET-OTM to Help Treat Opioid Use Disorder - HTML (w)

2019.01.07 | 06:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

VIFOR PHARMA

puce Vifor Pharma receives positive phase-I trial results for oral ferroportin inhibitor - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 1000